David White is a software/firmware/marketing professional and a long time investor. He has worked in the networking field, the semiconductor equipment field, the mainframe computer field, and the pharmaceutical/scientific instrumentation field. He has bachelor's degrees in bioresource sciences and biochemistry from U.C. Berkeley. He is a former Ph.D. student in biochemistry. He has done significant graduate work in EECS and business at Stanford (through SITN) and UC Santa Cruz. He was awarded a Certificate in Advanced Software Systems (about 1/3 of an MS in EECS) by the Stanford Computer Science Department. He also took most of Stanford's undergraduate Computer Science curriculum.
Ron Rowland is a portfolio manager with Flexible Plan Investments, Ltd., a Registered Investment Advisor specializing in active management, located in Bloomfield Hills, Michigan.
He has been providing market commentary and active investment advice since 1991. He is the founder and editor of Invest With An Edge, a website and weekly newsletter providing free actionable ideas for ETFs, and the home of ETF Deathwatch.
Additionally, he is the Executive Editor of the All Star Investor newsletter (http://allstarinvestor.com), a highly regarded paid subscription investment service he started in 1991.
Prescience Point's founders have over 25 years of combined Wall Street experience, and a significant track-record of successful short recommendations.
The sole focus of our company is to conduct comprehensive fundamental research, and uncover companies that are engaging in fraudulent or misleading business practices. We partner with leading hedge funds, private investigators, accountants, lawyers and industry experts to conduct our research process. We take an activist role to communicate our findings to regulators, shareholders, and other public constituents.
Our firm was founded on the belief that investors deserve full and complete honesty, transparency and accountability from corporations they invest with. We set high expectations and standards for our research process and opinions, and strive to achieve the respect from our readers for our integrity, intellectual honesty, analytical rigor, and accuracy of our conclusions.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com, and on most days is still ranked in the top 5%. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. As the founder of Goldman Small Cap Research, Rob's routinely writes about small cap and micro cap companies. During his tenure as a sell-side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
Dr. Thomas K. Carr (aka “Dr Stoxx”) is the Founder of DrStoxx.com (formerly “Befriend the Trend Trading”). He holds M.Phil. and D.Phil. degrees from the University of Oxford. For 16 years he was a tenured professor and department chair. He currently is a fulltime trader, market analyst, trading systems developer, and trainer of traders. His management company, Kingdom Capital (est. 2012), manages “The 8:18 Fund”.
Dr. Carr is author of two bestselling trading books: "Trend Trading for a Living" (McGraw-Hill, 2007) and "Micro-Trend Trading for Daily Income" (McGraw-Hill, 2010). They have been translated into Chinese, Japanese and Korean. His new book, "Market-Neutral Trading", was just published. Dr. Carr’s insights into the markets have been published in "The Wall Street Journal", "US News and World Report", "Investors Business Daily", and "Technical Analysis of Stocks and Commodities".
Hedge fund trader and analyst specializing in REIT, hotel, home building, real estate, financial, and consumer discretionary stocks. Preferred stock expert. Extensive experience investing using a variety of typical hedge fund strategies including long/short equity, merger arbitrage, capital structure arbitrage and distressed debt. Formerly, adjunct professor of Finance and Accounting at SUNY, Empire State College.
I'm an independent equity researcher, writer and investor based in Amsterdam. My primary focus is on the micro-cap segment of the market. I also work for pension funds as a member of the Board and Investment Committee. Lastly, I enjoy soccer, sports in general and brewing the best coffee one can make at home.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories.
Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar.
In his leisure time Tom enjoys playing racquetball on a competitive level.
Mr. Leach spent his early years on a subsistence farm in western Michigan. He graduated at the top of his high school class which helped him land a scholarship to the University Michigan. Graduating magna cum laude with a bachelor’s degree in Nuclear Engineering and a minor in mathematics in 1981, Mr. Leach took his first professional job with Westinghouse Electric in Monroeville, PA.
Mr. Leach held several positions of increasing responsibility at Westinghouse, and Fluor Federal Services in Pennsylvania, South Carolina, and Washington State. While in Washington State, Mr. Leach completed his master’s of science degree in Environmental Engineering graduating summa cum laude in 1997 from Washington State University.
In 2003 and 2004 with Fluor Federal Services, Mr. Leach worked as a civilian contractor for the US Department of Defense in various middle east locations and the Philippines. In 2005, Mr. Leach joined the AREVA Group and spent two years in France. After returning stateside in 2006, Mr. Leach held various positions of increasing responsibility with AREVA Federal Services in South Carolina and North Carolina. Mr. Leach left the AREVA group in 2014 at the age of 56 and is now quasi-retired and focuses on his wife, his 15 year old son, and his investment portfolio.
Mr. Leach has been a consistent, avid, and successful investor for more than 30 years. His investment style is conservative and he primarily invests in income oriented equities, bonds, preferred stocks and mutual funds. Mr. Leach has written more than 50 articles on Seeking Alpha and other websites.
Self-directed, began in mid 90s in drips. Then employer 401k. Rolled to self in 2010, invested in all div stocks.
Buy and hold (so far), I am a dividend-lover that has always aspired to live off my divs.
My Roth includes some hedges that began as experiments: 2 TIPS funds out of sheer curiosity , 2 govt bond funds (med and LT), and one bond index ETF. I have always been 90%+ stocks (or stock funds in 401k) , currently 98% equities. I let the workplace 401k handle international exposure and otherwise diversify within each portfolio, and across entire holdings.
Each stock owned in only one acct; multiple portfolios taxable and retirement; position sizes and start/add dates vary widely, not all positions receive new money:
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
Jeffrey Saut is Chief Investment Strategist and Managing Director of Equity Research at Raymond James & Associates.
Mr. Saut began his career on a trading desk in New York City. In 1973, he joined E.F . Hutton, where he began following equities and writing research. He subsequently worked as a securities analyst for Wheat First Securities, and then Branch Cabell, where he ran the equity research group as director of research and acted as portfolio manager for the firm's affiliate, Exeter Capital Management. As director of research, he built the research and institutional sales departments for the regional brokerage firm Ferris, Baker and Watts, Inc. and subsequently Sterne, Agee & Leach, Inc.
Mr. Saut is well known for his insightful and colorful commentary regarding the stock market, and he makes regular media appearances.
Note: Mr. Saut is not an active contributor to Seeking Alpha; rather, SA editors excerpt regularly from Mr. Saut's public commentary.
I am a petroleum engineer by degree and focus mostly on oil and gas related stocks. I intend to use my education and experience in the oil and gas field to help other investors properly evaluate oil & gas stocks and funds.
I welcome any comments, thoughts, or suggestions!
Mohit Manghnani is presently a full time editor at Seeking Alpha. He covers the new IPO's and follows live market commentary. Before joining Seeking Alpha, Mohit worked with a start-up - Research firm where he worked in the capacity of a Team Leader tracking company events and results.
Born in the U.A.E, Mohit spent most of his growing up years in Dubai. Currently, he resides in Mumbai, India and is pursuing his charter in Accountancy.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
Managing partner of Quintessential Capital Management, an investment fund, and Zanshin Capital, an asset management company both focusing on long-only, absolute return, equity investments with a value approach.
I have started investing from an early age, but only in 2005 did I discover the wisdom and effectiveness of value investing. After reading every book I found on the subject, I studied for a short, but extremely profitable period, under the guidance of Prof. Bruce Greenwald of Colombia University, who specializes in value investing.
The core positions in my portfolio are classic Buffett-style franchises acquired at a discount and kept indefinitely. The idea is acquiring a company in a slow-changing industry with a protective moat and letting it compound for years.
Occasionally, I go for "cigar butt"-style investments, where a mediocre company is acquired at a steep discount. But, in general, I prefer the former type.
I focus on US stocks but do keep my eyes open for global opportunities as well.
Brian Marckx, CFA is the Senior Medical Device / Diagnostics Analyst with Zacks Investment Research. I cover small and micro-cap medical device and diagnostic companies. Focus is development-stage companies with novel and emerging technologies as well as already established names still flying under the radar.
Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks.
Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian is also a Chartered Financial Analyst charterholder.
Red Acre applies value investing principles to mirco-cap and binary event investing.
Our Chief Investment Officer is Rajesh Patel. Prior to Red Acre, Rajesh was a Member of Technical Staff with the Massachusetts Institute of Technology, (MIT) Lincoln Laboratory where he analyzed the strategic value of emerging technologies to enhance the capabilities of the U.S. Military. Rajesh holds a Ph.D. in Applied Physics from the University of California, Davis, a Master's in Environmental Science from Rice University and bachelors degrees in both Physics and English from the University of Connecticut.
Red Acre's investment style is to look for opportunities where the intrinsic value of a stock is likely to go through a dramatic transition due to some future event about which we can predict an outcome relying on our research and due diligence experience. We are patient investors and are comfortable with having time horizons of several months to over a year for our investment thesis to fully play out.
I like to look for situations where I think the market is not accurately reflecting the true fundamentals of a company. I buy all my ideas in my own account before writing about them, so investors should be aware of this. I will also sell them before telling others, so, once again, please keep this in mind if you're following my ideas.